June 2, 2022

Lymphoma is a common cancer that includes Hodgkin lymphoma (HL), among others. Excisional lymph node biopsy, immunohistochemistry, and in situ hybridization are used to diagnose and classify lymphoma. However, invasive biopsies have significant limitations and risks, and they do not take into account differences between and within tumors because they only take a sample from...

There is insufficient data to address the incidence rate and risk factors for secondary lung cancer among Hodgkin lymphoma survivors. In this study, published in the Journal of Clinical Oncology for the 2022 ASCO Annual Meeting, data from a cohort of Hodgkin lymphoma patients diagnosed between 1973 and 2015 were investigated using the Surveillance Epidemiology and End...

Patients who receive chimeric antigen receptor (CAR) T-cell therapy or allogeneic stem cell transplants (allo-SCT) often exhibit some form of immunosuppression as a result of their treatment or transplant. In the era of COVID-19, severe disease has emerged as a grave concern in high-risk CAR T-cell therapy and allo-SCT patients who may have weakened immune...

CAR T-cell therapy has gained attention as an increasingly promising cellular therapy. However, while CAR T-cells are highly targeted and effective treatments for certain cancers, they often face mounting obstacles from the tumor microenvironment (TME). Tumors release different immune-suppressing molecules and disrupt the activity of CAR T-cells and other tumor-infiltrating lymphocytes (TILs). Another factor to...